Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 06 Sep 2022
Boston Scientific receives FDA approval for expanded labelling of Watchman FLX LAAC device for dual anti-platelet therapy as post-procedural medication option
6 September 2022 - Watchman FLX now the only LAAC technology in the United States that allows for either dual anti-platelet ...
Posted by Michael Wonder on 06 Sep 2022
PHARMAC capable of managing medical devices supply chain, it says
6 September 2022 - PHARMAC says it has saved $100 million since 2014 by doing deals to cut the price ...
Posted by Michael Wonder on 06 Sep 2022
COVID-19: a global opinion on bivalent vaccines in mid-September
5 September 2022 - The EMA has just modified the marketing authorisations granted to messenger RNA vaccines developed by Moderna and ...
Posted by Michael Wonder on 06 Sep 2022
Sanofi sees EU regulatory decision on its COVID booster in weeks
5 September 2022 - The European Union's drugs regulator may be a few weeks from deciding whether to approve the ...
Posted by Michael Wonder on 06 Sep 2022
Swissmedic authorizes Novavax Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as a booster in adults aged 18 and older
5 September 2022 - Novavax, today announced that Swissmedic has expanded its temporary authorisation of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in Switzerland ...
Posted by Michael Wonder on 06 Sep 2022
Amazon eyes Japan's online prescription drug market
5 September 2022 - E-commerce giant considers creating platform with local pharmacies. ...
Posted by Michael Wonder on 05 Sep 2022
New PM will ‘inherit an NHS in its most challenging state for decades’
5 September 2022 - Warning comes from NHS leaders as new Prime Minister prepares to move into Number 10. ...
Posted by Michael Wonder on 05 Sep 2022
Clinical trials: real world data plays early role in efforts to increase diversity
5 September 2022 - The use of real world data to help design clinical trials is nothing new but increasingly it ...
Posted by Michael Wonder on 05 Sep 2022
PHARMAC promises equity boost in first official response to independent review
6 September 2022 - PHARMAC will supercharge its commitment to Māori and diverse communities, which could see different medicines funded, ...
Posted by Michael Wonder on 05 Sep 2022
PHARMAC releases its interim response following PHARMAC review
5 September 2022 - As part of its ongoing commitment to transparency, Te Pātaka Whaioranga – PHARMAC has today shared their ...
Posted by Michael Wonder on 05 Sep 2022
International work-sharing - first medicines approved by all five Access Consortium regulators
2 September 2022 - The TGA has approved two new medicines as part of the Access New Active-Substance Work-Sharing Initiative. ...
Posted by Michael Wonder on 05 Sep 2022
Forxiga approved in China for the treatment of chronic kidney disease in patients at risk of progression with and without type 2 diabetes
5 September 2022 - Approval marks the first SGLT-2 inhibitor approved in China for chronic kidney disease in adult patients ...
Posted by Michael Wonder on 05 Sep 2022
Review of Efficient Funding of Chemotherapy Program - interim report
5 September 2022 - The Efficient Funding of Chemotherapy review seeks to investigate current processes involved in the production, distribution ...
Posted by Michael Wonder on 05 Sep 2022
Collaboration arrangement between the Department of Health and Aged Care and Health Technology Assessment bodies in the United Kingdom and Canada
5 September 2022 - The Department of Health and Aged Care has signed an international collaboration arrangement with five like minded ...
Posted by Michael Wonder on 04 Sep 2022
Australia among world's best in treating debilitating and often fatal muscle disorder
4 September - Australia has become one of the first countries in the world to fund a new, next-generation treatment ...